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Abstract
Background: Nitric oxide (NO) is a multifunctional molecule synthesized by three isozymes of
the NO synthase (NOSs) acting as a messenger/modulator and/or a potential neurotoxin. In
rodents, the role of NOSs in sleep processes and throughout aging is now well established. For
example, sleep parameters are highly deteriorated in senescence accelerated-prone 8 (SAMP8)
mice, a useful animal model to study aging or age-associated disorders, while the inducible form of
NOS (iNOS) is down-regulated within the cortex and the sleep-structures of the brainstem.
Evidence is now increasing for a role of iNOS and resulting oxidative stress but not for the
constitutive expressed isozyme (nNOS). To better understand the role of nNOS in the behavioural
impairments observed in SAMP8 versus SAMR1 (control) animals, we evaluated age-related
variations occurring in the nNOS expression and activity and nitrites/nitrates (NOx-) levels, in
three brain areas (n = 7 animals in each group). Calibrated reverse transcriptase (RT) and real-time
polymerase chain reaction (PCR) and biochemical procedures were used.
Results: We found that the levels of nNOS mRNA decreased in the cortex and the hippocampus
of 8- vs 2-month-old animals followed by an increase in 12-vs 8-month-old animals in both strains.
In the brainstem, levels of nNOS mRNA decreased in an age-dependent manner in SAMP8, but not
in SAMR1. Regional age-related changes were also observed in nNOS activity. Moreover, nNOS
activity in hippocampus was found lower in 8-month-old SAMP8 than in SAMR1, while in the cortex
and the brainstem, nNOS activities increased at 8 months and afterward decreased with age in
SAMP8 and SAMR1. NOx- levels showed profiles similar to nNOS activities in the cortex and the
brainstem but were undetectable in the hippocampus of SAMP8 and SAMR1. Finally, NOx- levels
were higher in the cortex of 8 month-old SAMP8 than in age-matched SAMR1.
Conclusion: Concomitant variations occurring in NO levels derived from nNOS and iNOS at an
early age constitute a major factor of risk for sleep and/or memory impairments in SAMP8.
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Background
Aging is defined by an increase in the probability of death
over time associated with characteristic changes in pheno-
type [1]. Sleep alteration is a common phenomenon
observed in humans and animals during aging and is
often associated with impaired learning and memory [2].
The oxidative stress resulting from the loss of control of
reactive oxygen species (ROS) and the production of nitric
oxide (NO), when produced in excess and not balanced
by antioxidants, represent an attractive process responsi-
ble, at least partially, for the above impairments during
aging or related disorders such as Alzheimer disease (AD)
[3]. Our recent data obtained in aged rats [4] and in senes-
cence accelerated prone 8 mice (SAMP8) [5], a model of
early onset of human diseases [6], support such an
hypothesis.
NO is an intracellular multifunctional molecule involved
in both physiological and neurodegenerative processes of
the CNS. The dynamic of the NO release taking place in
the thalamus and the cortex [7,8] and/or locally in the
basal forebrain of the rat [9] has been pointed as determi-
nant in the modulation/regulation of the sleep-wake
states and the maintenance of the brain homeostasis. In
using pharmacological approaches (intraperitoneal, sub-
cutaneous or local injections of NO donors or inhibitors)
or KO mice, it has been, indeed, established that modula-
tions of nitric oxide synthases (NOS), affect the sleep
architecture in rodents. From these studies, NO derived
from the neuronal NOS isoform (nNOS) is confirmed as
a powerful sleep-facilitating agent whereas, NO produced
by the inducible NOS (iNOS) plays a major role in trigger-
ing and maintenance of rapid-eye movement sleep (REM)
during aging. Thus, nNOS and iNOS have complementary
roles in the regulation of the sleep-wake cycle [9-14].
However, NO can also be neurotoxic and implicated in
neurodegenerative diseases according to its free radical
properties [3]. Previous studies have shown that NOSs
expression is altered in AD. For example, in humans, neu-
rons in the entorhinal cortex and hippocampus, that are
vulnerable to neurodegeneration, express low levels of
nNOS while iNOS plays a role in the formation of plaques
and neurofibrillary tangles [15,16]. A similar pattern of
NO dysfunction is observed in the senescence-accelerated
mouse (SAM), a model of accelerated aging. In this way,
various findings have suggested that accumulation of the
damages exerted by NO-derived from iNOS together with
the alterations resulting from glutamate signaling and
cholinergic deficits lead to the degeneration of neurons
and glia in brain. These impairments are also accompa-
nied by learning and memory deficits occurring before the
median age of survival of SAMP8 mouse [17,18]. By con-
trast to iNOS, it is still unclear whether nNOS is causally
linked with the hippocampal dysfunction, the behavioral
deficits and the neuronal death. The results obtained vary
from an increase to a significant reduction in the nNOS
activity and the protein content in the cerebral structures
of the aged rat or SAM mouse [19-22].
In the present study, we evaluated the age-related varia-
tions occurring in nNOS expression and activity, nitrites/
nitrates levels (NOx-) in the frontal cortex, the hippocam-
pus and the brainstem of SAMP8 or senescence acceler-
ated-resistant (SAMR1, controls aging normally) mice.
Together with previous data [13], results obtained point
out that SAMP8 unlike SAMR1 are exposed at an early
stage to alterations of the NO derived from nNOS and
iNOS. Such alterations might be causally linked to the
senescence-related impairments and the degeneration
observed in the brain of SAMP8.
Results
Age-dependent mRNA expression
Data from RT-PCR are shown in Fig. 1A. From 2 to 8
months of age, a significant decrease (P < 0.01) in nNOS
mRNA level was seen in the three brain areas of SAMP8
but only in the cortex and the hippocampus of SAMR1.
From 8 to 12 months, nNOS mRNA level was reduced (P
< 0.01) in the brainstem of SAMP8 while a significant
increase (P < 0.01) takes place in the cortex and hippoc-
ampus of SAMP8 and SAMR1. When comparisons were
made between 2-vs 12-months of age, results indicate that
nNOS mRNA level was reduced (P < 0.01) in the hippoc-
ampus but increased (P < 0.01) in the cortex of SAMP8
and SAMR1. In 12 month-old animals, nNOS mRNA level
was significantly lower (P < 0.01) in the hippocampus but
significantly higher (P < 0.01) in the cortex than in 2
month-old ones. By contrast, nNOS mRNA level was
lower (P < 0.01) in the brainstem at 12-vs 2 months of
age, only in SAMP8.
Age-dependent nNOS activity and NO-x production
The profiles of age-related changes occurring in nNOS
activity are given in Fig. 1B. In SAMP8, nNOS activity
increased (P < 0.01) in the cortex and the brainstem from
2 to 8 months, and then decreased (P < 0.01) in 12-vs 2 or
8 month-old mice. By contrast, nNOS activity markedly
decreased (P < 0.01) in the hippocampus at 8-vs 2 months
of age and remained low with age. In SAMR1, nNOS activ-
ity did not change significantly in the cortex and the brain-
stem from 2 to 8 months but afterward, it decreased (P <
0.01) with age. So, nNOS was lower (P < 0.01) in12-vs 2
or 8 month-old SAMR1.
The variations occurring in NOx- levels are shown in Fig.
1C. NOx- levels were higher (P < 0.01) in the cortex and
the brainstem of 8-vs 2 month-old SAMP8 and SAMR1,
the maximal increase (P < 0.01) occurred in the cortex of
SAMP8 and was followed by a decrease with age. So, NOx-BMC Neuroscience 2006, 7:81 http://www.biomedcentral.com/1471-2202/7/81
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Biochemical characterization of nNOS during aging in the cortex, the hippocampus and the brainstem of SAMR1 and SAMP8 Figure 1
Biochemical characterization of nNOS during aging in the cortex, the hippocampus and the brainstem of 
SAMR1 and SAMP8. nNOS mRNA levels in arbitrary units (A.U.) (A), nNOS enzymatic activity in pmol of citrulline per 
minute per mg of protein (B) and Nitrites and nitrates (NOx) levels in nmol per mg of tissue (C) were detected in SAMR1 
(solid line and open box) and SAMP8 (dotted line and dark box). Data are mean ± S.E.M) (n = 7 mice in each group). Statistics: 
significantly different from 2 months *P < 0.05, ** P < 0.01; or from 8 months aP < 0.05, bP < 0.01; significantly different from 
strain cP < 0.01.
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levels were lower in the cortex (P < 0.01) and the brain-
stem (P < 0.01) of 12-vs 8 month-old SAMP8 and SAMR1.
Finally, NOx- levels were higher (P < 0.01) in the cortex of
8 month-old SAMP8 than in age-matched SAMR1. In the
hippocampus, NOx- were undetectable (limit of detec-
tion: 1 pmol/mg of tissue) in both SAMP8 and SAMR1.
Discussion
In the central nervous system NO is produced by NOSs.
Three different isozymes have been identified and nNOS
accounts for the majority of the physiological actions of
NO [20]. It is well documented that nNOS and iNOS have
complementary roles in sleep regulation, learning and
memory [9,14,15,21] and neuronal death in neurodegen-
erative disorders [3,23]. Previously, we demonstrated that
the loss of iNOS activation is responsible to sleep impair-
ments (i.e low quantities of REM sleep) at an early age in
SAMP8 [13]. To extend our previous hypothesis on the
putative role of NO in the accelerated brain aging of
SAMP8, in this study, we examined the age-related
changes occurring in the nNOS expression and activity
and NO-x levels within the brainstem sleep-structure, the
cortex and the hippocampus of SAMP8 and compared
them to age-matched SAMR1. The main findings obtained
indicate the existence of biphasic changes in NO metabo-
lism: 1- a down-regulation of nNOS mRNA at 8 months
of age followed by a slight up-regulation with age except
within the brainstem; 2- an increase in nNOS activity and
NOx- levels, followed by a decrease with age, in the cortex
and the brainstem in SAMP8 and SAMR1. By contrast, our
data show a marked decrease in nNOS activity in the hip-
pocampus at 8 months of age, i.e. well before aging, only
in SAMP8. These results agree with previous data and sug-
gest that the down-regulation of nNOS activity at an early
age is causally linked with accelerated brain aging in
SAMP8. The fact that nNOS activity remains constant with
age reinforces such an evidence [15,19-22]. However, our
present data also indicate that: -nNOS mRNA levels are
not well correlated with activity values; NO-x levels are
undetectable in whole hippocampi. This latter point, sug-
gests that a more appropriate dissection is necessary to
consider the part played by NO in the dorsal hippocam-
pus and mainly in which regards the spatial information
processing. Other studies conducted in human and
rodents agree with our present findings. In this sense, it
has been reported that: 1- different regions behave differ-
ently during aging and/or degeneration [16]; 2- nNOS
expression and synthesis can be regulated by Ca2+fluxes
independently from nNOS activity especially in the hip-
pocampus [24]; (c) there is a post-transcriptional regula-
tion of nNOS expression in the brain of SAM [17].
In the same way, the neurotoxicity of NO has been now
extensively investigated and it appears that the NO pro-
duction confers resistance to glutamate excitotoxicity
[25]. Behind this observation, the precise mechanisms
involved still remain unclear. Recently, it has been
reported that neurons of the entorhinal cortex and the
hippocampus, expressing low levels of nNOS, are highly
vulnerable to degeneration, [15,16]. Other studies have
shown that nNOS activity increases in several brain
regions of aged SAMP8, SAMP10 and rats [17,22,26] sug-
gesting that the increase production in NO can lead to an
increased release of glutamate in the brain with aging
[25]. On the other hand, studies have reported that iNOS
expression is altered in AD and is implicated in the forma-
tion of plaques and fibrillary tangles [27]. Several mecha-
nisms are involved in the neurotoxic effects exerted by
NO. This free radical can combine with superoxide to
form peroxynitrite, another highly destructive radical
moiety. The resultant ROS can induce oxidative stress and
cause lipid peroxydation, functional alterations in pro-
teins and DNA and an eventual neuronal death. A dys-
function of Ca2+  homeostasis supports also the link
between NO and AD since Ca2+ is the primary regulator of
nNOS expression [3]. Furthermore, a relation between
amyloid-β (Aβ) on NO production has been discussed.
Recently, it has been reported the contribution of Aβ the
cognitive decline in the aged SAMP8, since a reduction of
Aβ by antibody or antisense oligonucleotides, reduces oxi-
dative stress and improves learning and memory [6]. Our
present results extend the observation that nNOS may be
involved in the oxidative stress observed in the brain of
SAMP8 and highlight the possibility that reduced NO/
nNOS synthesis within the hippocampus at an early age
may be a marker of vulnerability. These points need fur-
ther investigations based on behavioral tests coupled with
histochemical and/or biochemical analyses. Concerning
the brainstem-sleep structures, our data support the idea
that the sleep deterioration observed in the SAMP8, may
result from complementary iNOS and nNOS alterations
i.e a down-regulation of iNOS [13] concomitant with an
activation of nNOS activity at an early age. By contrast,
evidence supports the hypothesis that the NO synthesis
derived from iNOS activity and its release, taking place
within the brainstem, play a determinant role in the regu-
lation of the sleep-wake states in SAMR1 aging normally
[13,19].
Finally, NO emerges as a bi-functional regulator of apop-
tosis but, in the brain, it exerts only a pro-apoptotic effect
during aging. Although the mechanisms behind its action
have been investigated, the downstream mediators in NO-
induced apoptosis are not yet well defined. Nonetheless,
it has been reported that a high NO production, by up-
regulation of nNOS expression promotes Bcl-2-linked
apoptosis in the cortex of SAMP10 and causes an acceler-
ated aging of the brain [22]. However, there is no signifi-
cant difference in the expression of pro-apoptotic protein
p53 content values between SAMP10 and SAMR1 [22] asBMC Neuroscience 2006, 7:81 http://www.biomedcentral.com/1471-2202/7/81
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observed in SAMP8 (unpublished results). More recently,
it has been suggested that other factors such as low glial
cell line-derived neurotrophic factor (GDNF) as well as
other neurotrophines such as neurotrophine-3 and nerve
growth factor [28] are involved in hippocampal dysfunc-
tion and neuronal death (including apoptosis in the hip-
pocampus) in SAMP8. Regarding other structures, several
indices of oxidative stress as well as alpha synuclein and
hyperphosphorylated tau protein could rely to the senes-
cence-related impairments and neurodegeneration in
SAMP8 [29].
Conclusion
Many alterations of the gene expression and protein
abnormalities, such as deposition of Aβ-peptide, with rel-
evance to age-related cognitive decline have been found in
the brain of SAMP8. Interestingly, all studies support the
hypothesis that oxidative stress leads to cognitive dysfunc-
tion. Our present findings together with previous data
[13] demonstrate that SAMP8 unlike SAMR1 are really
exposed at an early stage of their life to alterations of the
NO metabolism. Therefore, we propose that concomitant
variations occurring in NO levels derived from nNOS and
iNOS at an early age constitute a major factor of risk for
sleep and/or memory impairments.
Methods
Animals
Male SAMP8 and SAMR1 derived from AKR/J strain were
obtained from INRA-Dijon, (colony providing from
Kyoto University (Japan). Immediately after arrival (3
weeks of age), animals were maintained in individual
cages and placed in a sound-isolated room (22°C ± 1°C;
light-dark schedule 12 h- 12 h, light-on at 05. 00 h a.m.,
food and water ad libitum). The animals use and proce-
dures were conducted according to the EEC Directive (86/
609/EEC). Efforts were made to minimize the animal
number, pain and discomfort. Two series of animals (7
animals/group) were sacrificed between 10.00 and 12.00
h, a convenient interval time for nNOS activity did not
exhibit diurnal variations. Their brains were quickly
removed and dissected on ice according to Glowinski and
Iversen's method [30], i.e. frontal cortex, whole hippoc-
ampus and brainstem were separated from the whole
brain and retained for assays. All samples were frozen on
dry ice and stored at -80°C until RNA extraction and bio-
chemical measurements.
Reverse transcriptase polymerase chain reaction (RT-PCR)
The main procedure was similar to our previous descrip-
tion [13]. Briefly, total RNA was isolated from all tissues
using the Trizol reagent (Invitrogen, USA) according to
the manufacturer's instructions. To remove any genomic
DNA contamination, total RNA was treated with RNAse-
free DNAse I treatment (Qiagen) and purified using
RNAeasy mini columns (Qiagen). Total RNA concentra-
tion was carefully determined by measuring A260 in a
total volume of 50 μL using a Biophotometer (Eppendorf)
and disposable RNAse-free UVettes. A260/A280 was also
determined for each sample, and the values ranged
between 1.81 and 1.90, without any difference between
groups of mice. Using oligod(T)15, first-strand cDNAs
were obtained from the reverse transcription of mRNAs
contained in 500 ng of respective total RNAs (from the
three brain regions in both SAMP8 and SAMR1 (n = 7
mice) (126 individual cDNA syntheses) in the presence of
80 pg of a synthetic external non-homologous poly(A)
standard RNA (SmRNA) to normalize the reverse tran-
scription reaction of mRNA of biological samples accord-
ing to previous protocol [31]. All cDNA amplifications
were realized on 1/20th of the volume of the reverse tran-
scription (corresponding to 25 ng of the initial total RNA
solution). Real-time PCR amplification of nNOS-cDNAs
was performed on a LightCycler (Roche Diagnostics) and
was used to determine the initial concentration of tem-
plates in samples from a calibration curve (scale of nNOS-
cDNA concentration = 6 logs; PCR efficiency = 1.89 with
crossing points ranging from 16.51–34.71). The crossing
points of all samples were within the range of the calibra-
tion curve. Quantitect SYBR Green PCR kit (Qiagen) was
used, with the following parameters: 95°C for 15 min for
denaturation, 50 cycles at 94°C for 15 sec, primer-
dependent annealing temperature for 20 sec, 60°C for 20
sec and a final extension step at 72°C for 15 sec. Primers
used (forward: 5'-ACC CAA CGT CAT TTC TGT CC-3';
reverse: 5'-AAG GTG GTC TCC AGG TGT GT-3') for the
amplification of a 297 pb fragment of the mouse nNOS
cDNA were chosen according to GenBank access number
NM_008712. These primers yielded no PCR product on
all samples tested in this study when PCR amplification
were performed directly on 25 ng of total RNA (prior to
reverse transcription of mRNAs), excluding the possibili-
ties 1) that primer-dimer amplication occurred during
PCR, and 2) that PCR products resulted from genomic
DNA contamination. Using this primer pair, PCR amplifi-
cation provided a single DNA product which was identi-
fied by a uniform melting temperature (85.44°C). The
identity of the PCR product was confirmed by sequencing
(MWG Biotech). Results obtained for nNOS mRNA were
normalized against the SmRNA [31]. Results are expressed
in arbitrary units (A.U)
Measurements of nNOS activity and NOx- metabolites
In a second series, brains were dissected on ice and struc-
tures retained (see above) were homogenised and treated
as previously described [12]. Homogenates were centri-
fuged at 10 000 g for 45 min at 4°C to prepare crude
cytosol supernatants. Aliquots were then stored at -30°C.
Total NOS activity in the supernatant fluid was deter-
mined by measuring the conversion of [3H]L-arginine toBMC Neuroscience 2006, 7:81 http://www.biomedcentral.com/1471-2202/7/81
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[3H]L-citrulline in presence of calcium and calmodulin as
we have fully previously described [12,13]. All assays were
performed in duplicate. To determine the contribution of
iNOS (Ca2+-independent) to total NOS activity, calcium
was replaced with EGTA as previously described [13] and
constitutive NOS activity [cNOS activity = nNOS +
endothelial nitric oxide synthase (eNOS) activities] was
computed by subtracting it from the total NOS activity.
The preferential localization of eNOS to particulate frac-
tions, presumably plasma membrane rather than super-
natant fractions minimizes its contribution even if a
substantial level of particulate eNOS activity in the brain
regions particularly in hippocampus pyramidal cells can-
not be excluded [32]. nNOS (90% of cNOS) was
expressed in pmol cit/min/mg prot. An aliquot of the
supernatant fraction was used to determine the levels of
NOx- by Griess reaction as previously described [12]. Each
aliquot was deproteinised with NaOH and incubated for
30 min at 30°C in presence of Cu-coated Cd in order to
reduce NO3
- to NO2
-. Results are expressed as nmol/g tis-
sue. Protein concentration in supernatant fractions was
determined using Bradford's method [33].
Statistic analysis
All results are expressed as means ± standard errors of
means (S.E.M). Comparisons between groups were made
using the one-way analysis of variance ANOVA followed
by Bonferroni's test (multiple comparison). Differences
were considered significant at P < 0.05.
Abbreviations
The abbreviations used are: Aβ, amyloid beta; AD Alzhe-
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